Jiangsu Micromedmark Biotech Co., Ltd.

Micromedmark Biotech Co., Ltd.

Massachusetts Institute of Technology

Jiangsu Mircromedmark Biotech Co., Ltd.

Hongwei Gu

Chenyu Zhang

Ke Zeng

Timothy Manning Swager

Jin Wang

Liming Li

Danqing Liu

Xihan Li

Tianfu Zhang

Xueliang Wang

Minghui Cao

Yujing Zhang

Provided is an siRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia, and particularly, provided are a method of a tandem expression for siRNA of BTK, and an siRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia.

SiRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia

Provided is non-coded RNA of in-vivo infected microorganisms, parasitic microorganisms, symbiotic microorganisms and identification and application thereof. Also provided is a method of identifying the non-coded RNA of in-vivo pathogen sources. The invention also provided a pharmaceutical composition containing an inhibitor for specifically inhibiting or blocking a RNA sequence and a method to treat a pathogen infectious disease or parasitic disease by administering an inhibitor, which inhibits a non-coding RNA sequence derived from a pathogen in the body of an animal, to an animal subject in need thereof.

Inhibitor for inhibiting avian influenza virus and a pharmaceutical composition containing the same

The present invention providesnon-coding RNA and the identification and application thereof. In particular, the present invention proves through experiments that abacterium delivers non-coding RNAs (ncRNAs) encoded by the bacterium itself into a host cell, generates milRNAs similar to microRNAs by means of a microRNA splicing system in the cell, regulates the immune system with the milRNAs, and further protects thebacterium from being cleared by the host. Adsorbing milRNAs using milRNA inhibitors can effectively inhibit the survival ability of the bacterium in the cell, leading to a reduced vitality of the bacterium. The present invention further provides relevant reagents and methods for effective detection of, treatment to and study onbacteria orinfectious diseases.

[object Object]

The present invention provides drugs for treating AIDS, which comprises microvesicles carrying anti-HIV specific siRNA. The present invention also provides a preparation method of the drug.

Preparation of microvesicle-siRNA complexes and use thereof in AIDS treatment

Microvesicles containing interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing interfering RNAs are also provided. Microvesicles containing interfering RNAs, pharmaceutical compositions and kits comprising such microvesicles can be used to study the effects of interfering RNAs on receptor cells. As microvesicles containing interfering RNAs can stably, high efficiently and specifically deliver interfering RNAs, microvesicles containing interfering RNAs can be used to treat related diseases.

Microvesicles carrying small interfering RNAs, preparation methods and uses thereof

The present invention provides devices comprising an assembly of carbon nanotubes, and related methods. In some cases, the carbon nanotubes may have enhanced alignment. Devices of the invention may comprise features and/or components which may enhance the emission of electrons and may lower the operating voltage of the devices. Using methods described herein, carbon nanotube assemblies may be manufactured rapidly, at low cost, and over a large surface area. Such devices may be useful in display applications such as field emission devices, or other applications requiring high image quality, low power consumption, and stability over a wide temperature range.

Growing community of inventors

Beijing, China

Hongwei Gu